QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NASDAQ:NKTR

Nektar Therapeutics - NKTR Stock Forecast, Price & News

$4.68
-0.23 (-4.68%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.67
$4.88
50-Day Range
$3.17
$5.14
52-Week Range
$3.02
$19.37
Volume
1.55 million shs
Average Volume
3.35 million shs
Market Capitalization
$877.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.17

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
181.3% Upside
$13.17 Price Target
Short Interest
Healthy
10.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
1.12mentions of Nektar Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$334,277 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.16) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

271st out of 1,124 stocks

Pharmaceutical Preparations Industry

125th out of 555 stocks

NKTR stock logo

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Mizuho dropped their price target on Nektar Therapeutics from $8.00 to $6.00 and set a "neutral" rating on the stock in a research note on Monday, April 18th. StockNews.com raised Nektar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, August 11th. JPMorgan Chase & Co. downgraded Nektar Therapeutics from a "neutral" rating to an "underweight" rating in a research note on Monday, August 8th. SVB Leerink cut their price target on Nektar Therapeutics from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Monday, April 18th. Finally, The Goldman Sachs Group lowered shares of Nektar Therapeutics from a "neutral" rating to a "sell" rating and set a $3.00 price objective on the stock. in a research report on Monday, April 18th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, Nektar Therapeutics has a consensus rating of "Hold" and a consensus target price of $13.17.

Nektar Therapeutics Stock Performance

Nektar Therapeutics stock opened at $4.91 on Tuesday. Nektar Therapeutics has a fifty-two week low of $3.02 and a fifty-two week high of $19.37. The firm has a market capitalization of $920.16 million, a price-to-earnings ratio of -1.73 and a beta of 1.19. The stock's fifty day moving average is $3.93 and its two-hundred day moving average is $5.70.

Nektar Therapeutics (NASDAQ:NKTR - Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.85) EPS for the quarter, beating analysts' consensus estimates of ($1.01) by $0.16. The firm had revenue of $21.59 million for the quarter, compared to analysts' expectations of $22.75 million. Nektar Therapeutics had a negative net margin of 544.77% and a negative return on equity of 82.40%. The firm's revenue was down 23.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.69) EPS. As a group, sell-side analysts forecast that Nektar Therapeutics will post -2.16 EPS for the current fiscal year.

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Stock News Headlines

Nektar: Time To Abandon Ship
Nektar promotes internal executive to CFO role
Nektar Therapeutics Reports First Quarter 2022 Financial Results
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Company Calendar

Last Earnings
8/04/2022
Today
8/16/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
740
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$13.17
High Stock Price Forecast
$54.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+181.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
13 Analysts

Profitability

Net Income
$-523,840,000.00
Net Margins
-544.77%
Pretax Margin
-544.42%

Debt

Sales & Book Value

Annual Sales
$101.91 million
Book Value
$3.68 per share

Miscellaneous

Free Float
181,071,000
Market Cap
$877.06 million
Optionable
Optionable
Beta
1.19

Social Links















NKTR Stock - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 3 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price forecast for 2022?

13 brokerages have issued 1-year price objectives for Nektar Therapeutics' stock. Their NKTR share price forecasts range from $3.00 to $54.00. On average, they predict the company's share price to reach $13.17 in the next year. This suggests a possible upside of 177.8% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2022?

Nektar Therapeutics' stock was trading at $13.51 on January 1st, 2022. Since then, NKTR stock has decreased by 64.9% and is now trading at $4.74.
View the best growth stocks for 2022 here
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.16. The biopharmaceutical company had revenue of $21.59 million for the quarter, compared to the consensus estimate of $22.75 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 82.40% and a negative net margin of 544.77%. The firm's revenue for the quarter was down 23.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.69) EPS.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (8.83%), State Street Corp (4.66%), Principal Financial Group Inc. (0.63%), Edgestream Partners L.P. (0.57%), Northern Trust Corp (0.48%) and PDT Partners LLC (0.44%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Nicholson, John Northcott, Jonathan Zalevsky, Katharina Otto-Bernstein, Mark Andrew Wilson, Myriam Curet, R Scott Greer, Robert Chess and Stephen K Doberstein.
View institutional ownership trends
.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $4.74.

How much money does Nektar Therapeutics make?

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $888.28 million and generates $101.91 million in revenue each year. The biopharmaceutical company earns $-523,840,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

The company employs 740 workers across the globe.

When was Nektar Therapeutics founded?

Nektar Therapeutics was founded in 1990.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.